CN118119381A - 包含erk抑制剂的组合物 - Google Patents
包含erk抑制剂的组合物 Download PDFInfo
- Publication number
- CN118119381A CN118119381A CN202280070421.4A CN202280070421A CN118119381A CN 118119381 A CN118119381 A CN 118119381A CN 202280070421 A CN202280070421 A CN 202280070421A CN 118119381 A CN118119381 A CN 118119381A
- Authority
- CN
- China
- Prior art keywords
- weight
- compound
- solid dispersion
- solvate
- hpmcas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271977P | 2021-10-26 | 2021-10-26 | |
| US63/271,977 | 2021-10-26 | ||
| PCT/US2022/047769 WO2023076305A1 (en) | 2021-10-26 | 2022-10-25 | Compositions comprising an erk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118119381A true CN118119381A (zh) | 2024-05-31 |
Family
ID=84367494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280070421.4A Pending CN118119381A (zh) | 2021-10-26 | 2022-10-25 | 包含erk抑制剂的组合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240415835A1 (https=) |
| EP (1) | EP4422604A1 (https=) |
| JP (1) | JP2024539891A (https=) |
| KR (1) | KR20240089586A (https=) |
| CN (1) | CN118119381A (https=) |
| AU (1) | AU2022376165A1 (https=) |
| CA (1) | CA3235680A1 (https=) |
| WO (1) | WO2023076305A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) * | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
-
2022
- 2022-10-25 US US18/702,752 patent/US20240415835A1/en active Pending
- 2022-10-25 AU AU2022376165A patent/AU2022376165A1/en active Pending
- 2022-10-25 KR KR1020247015609A patent/KR20240089586A/ko active Pending
- 2022-10-25 EP EP22814554.6A patent/EP4422604A1/en active Pending
- 2022-10-25 CA CA3235680A patent/CA3235680A1/en active Pending
- 2022-10-25 CN CN202280070421.4A patent/CN118119381A/zh active Pending
- 2022-10-25 WO PCT/US2022/047769 patent/WO2023076305A1/en not_active Ceased
- 2022-10-25 JP JP2024523533A patent/JP2024539891A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022376165A1 (en) | 2024-05-16 |
| CA3235680A1 (en) | 2023-05-04 |
| US20240415835A1 (en) | 2024-12-19 |
| JP2024539891A (ja) | 2024-10-31 |
| EP4422604A1 (en) | 2024-09-04 |
| KR20240089586A (ko) | 2024-06-20 |
| WO2023076305A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118119381A (zh) | 包含erk抑制剂的组合物 | |
| JP3696087B2 (ja) | イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法 | |
| US20170000764A1 (en) | Pharmaceutical composition with improved bioavailability | |
| EP4090332B1 (en) | Compositions of substituted pyrazolopyrimidines and uses thereof | |
| KR102300335B1 (ko) | 아프레피탄트의 경구용 조성물 | |
| JP2023509560A (ja) | 高いバイオアベイラビリティを有するソラフェニブの医薬組成物及びその応用 | |
| TWI837095B (zh) | 一種醫藥組成物及其製備方法 | |
| CN114832112A (zh) | 含有alk激酶抑制剂的药物制剂组合物及其制备方法 | |
| HK40111112A (zh) | 包含erk抑制剂的组合物 | |
| JP7796751B2 (ja) | 非晶質固体分散体 | |
| TW202419085A (zh) | 含erk抑制劑之組合物 | |
| CN115397416B (zh) | 包含仑伐替尼的分子水平的药物组合物及其制备方法和应用 | |
| CN115025048A (zh) | 一种阿瑞匹坦的三元固体分散体 | |
| CN113679729A (zh) | 一种抗炎组合物及其制备方法 | |
| CN115844845B (zh) | 一种硝苯地平缓释制剂及制备方法 | |
| TWI901422B (zh) | 一種嘧啶類衍生物的藥物組合物 | |
| CN117257804A (zh) | 达拉非尼药物组合物及其制备方法和应用 | |
| EP4626434A1 (en) | Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide | |
| WO2026019402A1 (en) | A pharmaceutical composition comprising nanosuspension of canagliflozin | |
| TR2022009480A1 (tr) | Palbosiklib içeren bir farmasötik bileşim. | |
| KR20210084250A (ko) | 아프레피탄트의 용해도가 증가된 경구용 조성물 | |
| TR2022009483A2 (tr) | Palbosiklib içeren bir farmasötik bileşim. | |
| WO2026021558A1 (zh) | 一种药物制剂组合物及其制备方法 | |
| CN120983371A (zh) | 一种btk抑制剂固体片剂及其制备方法 | |
| TR2022009484A2 (tr) | Palbosiklib içeren oral uygulama için bir tablet. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40111112 Country of ref document: HK |